Axa
XENE icon

Axa’s Xenon Pharmaceuticals XENE Stock Holding History

Axa’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-175,632
Closed -$5.5M – 1038
2025
Q2 		$5.5M Buy
175,632
+282
+0.2% +$9.2K 0.02% 544
2025
Q1 		$5.88M Sell
175,350
-12,446
-7% -$473K 0.02% 507
2024
Q4 		$7.36M Sell
187,796
-294
-0.2% -$12.2K 0.02% 445
2024
Q3 		$7.41M Buy
188,090
+52
+0% +$2.1K 0.02% 453
2024
Q2 		$7.33M Buy
188,038
+166
+0.1% +$6.64K 0.02% 453
2024
Q1 		$8.09M Buy
187,872
+51
+0% +$2.35K 0.02% 449
2023
Q4 		$8.65M Sell
187,821
-4,542
-2% -$160K 0.03% 427
2023
Q3 		$6.57M Sell
192,363
-672
-0.3% -$25.1K 0.02% 478
2023
Q2 		$7.43M Buy
193,035
+2,655
+1% +$106K 0.02% 470
2023
Q1 		$6.81M Sell
190,380
-414
-0.2% -$15.3K 0.02% 487
2022
Q4 		$7.52M Sell
190,794
-1,042
-0.5% -$37.9K 0.03% 502
2022
Q3 		$6.93M Buy
191,836
+485
+0.3% +$17.4K 0.03% 510
2022
Q2 		$5.82M Sell
191,351
-3,701
-2% -$112K 0.02% 542
2022
Q1 		$5.96M Buy
195,052
+4
+0% +$120 0.02% 601
2021
Q4 		$6.09M Buy
195,048
+35,405
+22% +$1.06M 0.02% 615
2021
Q3 		$2.44M Buy
+159,643
New +$2.77M 0.01% 820

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Axa's XENE Position: Q3 2025 in Review

Axa sold out of Xenon Pharmaceuticals (XENE) in Q3 2025, closing a stake of 175,632 shares — an estimated $5.5M sold.

Axa first reported a position in XENE in Q3 2021 and held it in 16 quarters. The position peaked at $8.65M in Q4 2023. 219 funds tracked by Wall St. Rank hold XENE as of Q3 2025.

  • Axa reported no remaining Xenon Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Axa sold 175,632 Xenon Pharmaceuticals shares in Q3 2025, an estimated $5.5M.
  • Axa first reported a position in Xenon Pharmaceuticals in Q3 2021 and held it in 16 quarters.
  • Axa's Xenon Pharmaceuticals position peaked at $8.65M in Q4 2023.
  • 219 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q3 2025.

Based on Axa's 13F filing for Q3 2025, filed 14 Nov 2025.